{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:07:17Z","timestamp":1779178037636,"version":"3.51.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T00:00:00Z","timestamp":1294963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4\u2003:\u2003CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4+CD25+ regulatory T cells (Tregs) within the CD4+ population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4+CD25+ Tregs frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2010.04304.x","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T15:25:26Z","timestamp":1295018726000},"page":"375-380","source":"Crossref","is-referenced-by-count":12,"title":["Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model"],"prefix":"10.1093","volume":"163","author":[{"given":"D","family":"Bresson","sequence":"first","affiliation":[{"name":"Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M G","family":"von Herrath","sequence":"additional","affiliation":[{"name":"Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,1,14]]},"reference":[{"key":"2021122708482645200_b1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.immuni.2005.08.002","article-title":"A comprehensive review of interventions in the NOD mouse and implications for translation","volume":"23","author":"Shoda","year":"2005","journal-title":"Immunity"},{"key":"2021122708482645200_b2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nri1502","article-title":"Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes","volume":"4","author":"Roep","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2021122708482645200_b3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/1074-7613(94)90101-5","article-title":"How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model","volume":"1","author":"von Herrath","year":"1994","journal-title":"Immunity"},{"key":"2021122708482645200_b4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4049\/jimmunol.168.2.933","article-title":"Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance","volume":"168","author":"von Herrath","year":"2002","journal-title":"J Immunol"},{"key":"2021122708482645200_b5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2337\/db06-1384","article-title":"Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation","volume":"57","author":"Simon","year":"2008","journal-title":"Diabetes"},{"key":"2021122708482645200_b6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jviromet.2007.08.025","article-title":"Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivo","volume":"147","author":"McCausland","year":"2008","journal-title":"J Virol Methods"},{"key":"2021122708482645200_b7","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.4049\/jimmunol.165.10.5945","article-title":"Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes","volume":"165","author":"Holz","year":"2000","journal-title":"J Immunol"},{"key":"2021122708482645200_b8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.autrev.2006.09.013","article-title":"Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?","volume":"6","author":"Bresson","year":"2007","journal-title":"Autoimmun Rev"},{"key":"2021122708482645200_b9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.91.1.123","article-title":"CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice","volume":"91","author":"Chatenoud","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708482645200_b10","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.89.8.3434","article-title":"Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum","volume":"89","author":"Maki","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122708482645200_b11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaut.2006.03.001","article-title":"Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes","volume":"26","author":"Ogawa","year":"2006","journal-title":"J Autoimmun"},{"key":"2021122708482645200_b12","first-page":"271","article-title":"Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus","volume":"2","author":"Eisenbarth","year":"1985","journal-title":"Diabetes Res"},{"key":"2021122708482645200_b13","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1600-6143.2008.02404.x","article-title":"Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes","volume":"8","author":"Bellin","year":"2008","journal-title":"Am J Transplant"},{"key":"2021122708482645200_b14","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.2337\/db09-0160","article-title":"Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients","volume":"58","author":"Hilbrands","year":"2009","journal-title":"Diabetes"},{"key":"2021122708482645200_b15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.immunol.23.021704.115643","article-title":"The NOD mouse: a model of immune dysregulation","volume":"23","author":"Anderson","year":"2005","journal-title":"Annu Rev Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2010.04304.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/163\/3\/375\/41909418\/j.1365-2249.2010.04304.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/163\/3\/375\/41909418\/j.1365-2249.2010.04304.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:18:13Z","timestamp":1641053893000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/163\/3\/375\/6428902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,14]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,1,14]]},"published-print":{"date-parts":[[2011,2,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04304.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,3]]},"published":{"date-parts":[[2011,1,14]]}}}